<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">Inhibitors that target nucleosides or nucleotides are building blocks of viral nucleic acids and they have broad-spectrum activity against a wide range of coronaviruses as well as other viruses, in general. Mycophenolate (
 <bold>5</bold>, 
 <xref rid="fig0015" ref-type="fig">Fig. 3</xref>), is an immunosuppressant drug used to prevent rejection in organ transplantation. It inhibits inosine monophosphate dehydrogenase, a key rate-limiting enzyme in the 
 <italic>de novo</italic> purine synthesis pathway which converts inosine monophosphate to guanosine monophosphate 
 <xref rid="bib0415" ref-type="bibr">[83]</xref>. The active molecule, mycophenolic acid (
 <bold>46</bold>, see for structure 
 <xref rid="tbl0020" ref-type="table">Table 4</xref> ), exhibits broad-spectrum 
 <italic>in vitro</italic> anti-viral activity against various viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV) and arboviruses 
 <xref rid="bib0410" ref-type="bibr">[82]</xref>. Recently, mycophenolic acid was identified as a potential anti-MERS-CoV drug by a high-throughput screening approach and has a potent anti-MERS-CoV activity 
 <italic>in vitro</italic>
 <xref rid="bib0415" ref-type="bibr">[83]</xref>. However, a subsequent study in a non-human primate model did not provide a positive result as the treatment of MERS-CoV infected common marmosets with mycophenolic acid had a worse outcome than untreated animals did 
 <xref rid="bib0420" ref-type="bibr">[84]</xref>.
</p>
